Skip to content

Patent foramen ovale closure for epilepsy: a study based on genomics, proteomics and fMRI

Patent foramen ovale closure for epilepsy: a study based on genomics, proteomics and fMRI

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031396
Enrollment
Unknown
Registered
2020-03-30
Start date
2020-03-31
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 9 to 55 years; 2. To avoid structural lesions that induced epilepsy, choose patients with brain MRI-Negative manifestations; 3. The duration of epilepsy over 1 year; 4. Right to left shunt of PFO confirmed by transthoracic echocardiography

Exclusion criteria

Exclusion criteria: 1. The epilepsy patients with definite CNS etiologic causes such as hippocampal sclerosis, cerebral trauma, tumor, cerebrovascular diseases, degenerative diseases, immunologic disorders, demyelinating disorders, cerebral infection, and so on. Especially, given the common cause of epilepsy in China is cerebral infarction, the conditions that any probable lacunar infarct in MRI or suspicious history of transient ischemic attack(TIA); 2. Family history of epilepsy; 3. With medical history of heart diseases and central nervous system (CNS) organic diseases; 4. Left to right shunt of PFO or other cardiac diseases (such as atrial septal defect) found by TTE.

Design outcomes

Primary

MeasureTime frame
proteomics;fMRI;genomics;

Secondary

MeasureTime frame
Severity of seizures;

Countries

China

Contacts

Public ContactChen Lei

West China Hospital, Sichuan University

leilei_25@126.com+86 18980605819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026